| Project/Area Number |
15591718
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Nihon University |
|---|
Principal Investigator |
HACHIYA Takahiko Nihon University, School of Medicine, Assistant Professor, 医学部, 講師 (40228482)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HIRANO Daisaku Nihon University, School of Medicine, Assistant Professor, 医学部, 講師 (40228804)
TAKIMOTO Yikie Nihon University, School of Medicine, Professor, 医学部, 教授 (20059546)
|
|---|
| Project Period (FY) |
2003 – 2004
|
| Project Status |
Completed (Fiscal Year 2004)
|
| Budget Amount *help |
¥3,200,000 (Direct Cost: ¥3,200,000)
Fiscal Year 2004: ¥400,000 (Direct Cost: ¥400,000)
Fiscal Year 2003: ¥2,800,000 (Direct Cost: ¥2,800,000)
|
|---|
| Keywords | Localized prostate cancer / FISH / c-myc / FISH法 / 病理組織学的分化度 / 臨床的非再発率 / 疾患特定生存率 / 臨床的非再発生存率 |
|---|
| Research Abstract |
Genetic aberration such as amplification of c-myc has been commonly observed in advanced prostate cancer. The aim of this study was to elucidate chromosome 8 alteration, including a gain and amplification of 8q24 (c-myc gene), related to the progression and survival in localized (Stage T1-T_3N_0M_0) prostate cancer.
We used dual-probe fluorescence in situ hybridization with a centromere-specific probe for chromosome 8 (8cen), and with a region-specific probe for c-myc (8q24) to evaluate genetic changes in tumor samples from 65 patients who had undergone radical retropubic prostatectomy from 1986 to 2003. We classified the 8cen and c-myc copy numbers as normal, gain and amplification (AI-c-myc). AI-c-myc was strongly associated with higher histopathological grades and Gleason's scores (P=0.03,<0.01, respectively). Patients with the AI-c-myc had earlier disease progression (P=0.011) and earlier cancer death (P=0.02) than did patients with normal patterns. Therefore, identification of an AI-c-myc may serve as a potential marker of prostate cancer progression.
|
